electroCore (ECOR) vs Pulmonx (LUNG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
electroCore (ECOR) has outperformed Pulmonx (LUNG) over the past year, gaining 96.4% versus a gain of 1.7%. Over five years, ECOR leads with a -35.0% price change compared with -95.4% for LUNG. electroCore is the larger company by market cap ($85.7 million vs $77.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | LUNG |
|---|---|---|
| Share price | $9.51 | $1.81 |
| Market cap | $85.74M | $77.74M |
| 1-day change | -2.16% | -1.63% |
| YTD return | +116.72% | -18.10% |
| 1-year return | +96.36% | +1.69% |
| 5-year return | -35.01% | -95.38% |
| EPS (TTM) | $-1.65 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.70 | $2.89 |
| 52-week low | $4.41 | $1.13 |
| Distance from 52-week high | -25.12% | -37.37% |
| Analyst consensus | none | none |
| Avg. price target upside | +101.58% | +87.85% |
| Average volume | 82.13K | 477.25K |
| Shares outstanding | 9.02M | 42.95M |
| Employees | 83 | 296 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ECOR has outperformed LUNG by 94.7 percentage points over the past year.
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Healthcare · Medical Devices · 83 employees
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Healthcare · Medical Devices · 296 employees
ECOR vs LUNG FAQ
Which is bigger, electroCore or Pulmonx?
electroCore (ECOR) is larger, with a market capitalization of $85.74M compared with $77.74M for Pulmonx (LUNG).
Which stock has performed better over the past year, ECOR or LUNG?
ECOR returned +96.36% over the past 12 months, compared with +1.69% for LUNG (price return, excluding dividends). Past performance does not predict future results.
Are electroCore and Pulmonx in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.